Zimmer Biomet Holdings, Inc. (ZBH) 10-Year Financial Performance & Capital Metrics

ZBH • • Industrial / General

HealthcareMedical DevicesOrthopedic & Musculoskeletal DevicesJoint Reconstruction & Orthopedic Implants

AboutZimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.Show more

Revenue $7.68B +3.8%
EBITDA $2.28B +2.4%
Net Income $904M -11.7%
EPS (Diluted) 4.43 -9.2%
Gross Margin 71.46% -0.5%
EBITDA Margin 29.72% -1.4%
Operating Margin 16.74% -3.1%
Net Margin 11.77% -15.0%
ROE 7.24% -13.3%
ROIC 5.36% -1.6%
Debt/Equity 0.50 +7.6%
Interest Coverage 5.90 -7.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 2.8% through buybacks
✓Trading at only 1.4x book value

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.09%

5Y-0.77%

3Y3.99%

TTM5.47%

Profit (Net Income) CAGR

10Y2.3%

5Y-4.4%

3Y31.05%

TTM-25.69%

EPS CAGR

10Y0.56%

5Y-4.13%

3Y32.37%

TTM-23.19%

ROCE

10Y Avg3.67%

5Y Avg4.36%

3Y Avg5.76%

Latest6.85%

Peer Comparison

Joint Reconstruction & Orthopedic Implants

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SYKStryker Corporation	136.07B	355.82	45.85	10.23%	12.07%	13.51%	2.56%	0.68
SNNSmith & Nephew plc	13.54B	31.90	33.94	4.7%	6.88%	14.44%	4.48%	0.63
ZBHZimmer Biomet Holdings, Inc.	17.51B	88.34	19.94	3.85%	10.05%	6.31%	6.53%	0.50
CNMDCONMED Corporation	1.24B	40.03	9.40	5%	4.75%	6.35%	12.41%	0.94
DHAIDIH Holding US, Inc.	6.7K	0.00	-0.00	-2.5%	-13.8%
LFWDLifeward Ltd.	12.57M	0.69	-0.21	85.24%	-121.82%	-233.98%		0.05
ANIKAnika Therapeutics, Inc.	137.72M	9.55	-2.49	-0.73%	-40.83%	-22.5%		0.17
SNWVSANUWAVE Health, Inc.	245.02M	28.57	-4.06	59.99%	-17.06%		0.8%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	6B	7.67B	7.8B	7.93B	7.98B	6.13B	6.83B	6.94B	7.39B	7.68B
Revenue Growth %	0.28%	0.28%	0.02%	0.02%	0.01%	-0.23%	0.11%	0.02%	0.07%	0.04%
Cost of Goods Sold+	1.8B	2.38B	2.13B	2.27B	2.25B	1.82B	1.96B	2.02B	2.08B	2.19B
COGS % of Revenue	0.3%	0.31%	0.27%	0.29%	0.28%	0.3%	0.29%	0.29%	0.28%	0.29%
Gross Profit+	4.2B	5.29B	5.67B	5.66B	5.73B	4.3B	4.87B	4.92B	5.31B	5.49B
Gross Margin %	0.7%	0.69%	0.73%	0.71%	0.72%	0.7%	0.71%	0.71%	0.72%	0.71%
Gross Profit Growth %	0.22%	0.26%	0.07%	-0%	0.01%	-0.25%	0.13%	0.01%	0.08%	0.03%
Operating Expenses+	3.73B	4.47B	4.87B	5.63B	4.59B	4.22B	4.01B	4.22B	4.03B	4.2B
OpEx % of Revenue	0.62%	0.58%	0.62%	0.71%	0.58%	0.69%	0.59%	0.61%	0.55%	0.55%
Selling, General & Admin	2.66B	2.94B	3.1B	3.38B	3.34B	2.71B	2.84B	2.76B	2.84B	2.93B
SG&A % of Revenue	0.44%	0.38%	0.4%	0.43%	0.42%	0.44%	0.42%	0.4%	0.38%	0.38%
Research & Development	268.8M	365.6M	369.9M	391.7M	449.3M	322.8M	435.8M	406M	458.7M	437.4M
R&D % of Revenue	0.04%	0.05%	0.05%	0.05%	0.06%	0.05%	0.06%	0.06%	0.06%	0.06%
Other Operating Expenses	800.6M	1.16B	1.4B	1.86B	799M	1.18B	727.4M	1.06B	735.1M	834.5M
Operating Income+	467.3M	821.1M	799.3M	33.8M	1.14B	83.1M	860.3M	696.3M	1.28B	1.29B
Operating Margin %	0.08%	0.11%	0.1%	0%	0.14%	0.01%	0.13%	0.1%	0.17%	0.17%
Operating Income Growth %	-0.55%	0.76%	-0.03%	-0.96%	32.65%	-0.93%	9.35%	-0.19%	0.83%	0.01%
EBITDA+	1.18B	1.86B	1.86B	1.07B	2.14B	981.5M	1.8B	1.62B	2.23B	2.28B
EBITDA Margin %	0.2%	0.24%	0.24%	0.14%	0.27%	0.16%	0.26%	0.23%	0.3%	0.3%
EBITDA Growth %	-0.17%	0.58%	0%	-0.42%	1%	-0.54%	0.83%	-0.1%	0.37%	0.02%
D&A (Non-Cash Add-back)	712.4M	1.04B	1.06B	1.04B	1.01B	898.4M	937.7M	926.4M	951.7M	996.3M
EBIT	439.8M	754.6M	789.9M	18.2M	1.13B	106.9M	707.4M	568.3M	1.27B	1.25B
Net Interest Income+	-277.2M	-355M	-325.3M	-289.3M	-226.9M	-212.1M	-208.4M	-164.8M	-201.2M	-218M
Interest Income	9.4M	0	0	0	0	0	0	0	0	0
Interest Expense	286.6M	355M	325.3M	289.3M	226.9M	212.1M	208.4M	164.8M	201.2M	218M
Other Income/Expense	-314.1M	-421.5M	-334.7M	-304.9M	-231.7M	-188.3M	-361.3M	-292.8M	-210.4M	-249.1M
Pretax Income+	153.2M	399.6M	464.6M	-271.1M	905.8M	-105.2M	499M	403.5M	1.07B	1.04B
Pretax Margin %	0.03%	0.05%	0.06%	-0.03%	0.11%	-0.02%	0.07%	0.06%	0.14%	0.13%
Income Tax+	7M	95M	-1.35B	108.2M	-225.7M	-96M	53.5M	112.3M	42.2M	131.4M
Effective Tax Rate %	0.96%	0.77%	3.9%	1.4%	1.25%	1.32%	0.8%	0.57%	0.96%	0.87%
Net Income+	147M	305.9M	1.81B	-379.2M	1.13B	-138.9M	401.6M	231.4M	1.02B	903.8M
Net Margin %	0.02%	0.04%	0.23%	-0.05%	0.14%	-0.02%	0.06%	0.03%	0.14%	0.12%
Net Income Growth %	-0.8%	1.08%	4.93%	-1.21%	3.98%	-1.12%	3.89%	-0.42%	3.43%	-0.12%
Net Income (Continuing)	146.2M	304.6M	1.81B	-379.3M	1.13B	-9.2M	445.5M	291.2M	1.03B	905.2M
Discontinued Operations	0	0	0	0	0	-128.2M	-43.4M	-58.8M	0	0
Minority Interest	1.5M	1M	-300K	4.8M	4.7M	5.2M	5.7M	6.7M	7.7M	8.1M
EPS (Diluted)+	0.26	1.50	9.03	-1.86	5.47	-0.67	1.91	1.10	4.88	4.43
EPS Growth %	-0.94%	4.77%	5.02%	-1.21%	3.94%	-1.12%	3.85%	-0.42%	3.44%	-0.09%
EPS (Basic)	0.27	1.51	9.11	-1.86	5.52	-0.67	1.93	1.10	4.91	4.45
Diluted Shares Outstanding	189.8M	202.4M	203.7M	203.5M	206.7M	207M	210.4M	210.3M	209.7M	203.9M
Basic Shares Outstanding	187.4M	200M	201.9M	203.5M	205.1M	207M	208.6M	209.6M	208.7M	203.1M
Dividend Payout Ratio	1.07%	0.62%	0.11%	-	0.17%	-	0.5%	0.87%	0.2%	0.22%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.85B	4.67B	4.58B	4.43B	4.72B	5.08B	4.88B	4.43B	4.61B	4.67B
Cash & Short-Term Investments	1.62B	634.1M	524.4M	542.8M	617.9M	802.1M	378.1M	375.7M	415.8M	525.5M
Cash Only	1.46B	634.1M	524.4M	542.8M	617.9M	802.1M	378.1M	375.7M	415.8M	525.5M
Short-Term Investments	164.6M	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.45B	1.6B	1.54B	1.28B	1.36B	1.45B	1.26B	1.38B	1.44B	1.48B
Days Sales Outstanding	88.03	76.37	72.23	58.7	62.37	86.53	67.34	72.66	71.2	70.38
Inventory	2.25B	1.97B	2.08B	2.26B	2.38B	2.45B	2.15B	2.15B	2.39B	2.24B
Days Inventory Outstanding	456.93	301.79	356.26	362.53	386.45	490.33	399.93	388.08	417.79	372.35
Other Current Assets	0	0	0	0	0	0	772.6M	324.5M	366.1M	430M
Total Non-Current Assets+	21.31B	22.02B	21.45B	19.7B	19.91B	19.33B	18.57B	16.64B	16.89B	16.69B
Property, Plant & Equipment	2.06B	2.04B	2.04B	2.02B	2.08B	2.05B	1.84B	1.87B	2.06B	2.05B
Fixed Asset Turnover	2.91x	3.76x	3.83x	3.94x	3.84x	2.99x	3.72x	3.71x	3.59x	3.75x
Goodwill	9.93B	10.64B	10.67B	9.59B	9.6B	9.26B	8.92B	8.58B	8.82B	8.95B
Intangible Assets	8.75B	8.79B	8.35B	7.68B	7.26B	7.06B	5.53B	5.06B	4.86B	4.6B
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	563.8M	553.6M	379.5M	366.2M	909.8M	965.7M	2.25B	1.11B	1.12B	1.02B
Total Assets+	27.16B	26.68B	26.01B	24.13B	24.64B	24.42B	23.46B	21.07B	21.5B	21.37B
Asset Turnover	0.22x	0.29x	0.30x	0.33x	0.32x	0.25x	0.29x	0.33x	0.34x	0.36x
Asset Growth %	1.82%	-0.02%	-0.03%	-0.07%	0.02%	-0.01%	-0.04%	-0.1%	0.02%	-0.01%
Total Current Liabilities+	1.62B	2.38B	3.07B	2.42B	3.44B	2.56B	3.47B	2.36B	2.86B	2.45B
Accounts Payable	284.8M	364.5M	330.2M	362.6M	400.9M	330M	306.5M	354.1M	410.6M	194.6M
Days Payables Outstanding	57.73	55.86	56.51	58.25	64.96	66.03	57.07	64	71.92	32.42
Short-Term Debt	0	575.6M	1.23B	525M	1.5B	500M	1.61B	544.3M	900M	863M
Deferred Revenue (Current)	0	0	0	0	0	1000K	0	0	0	0
Other Current Liabilities	144.1M	168M	319.1M	460.4M	321.7M	329.8M	640.5M	502.8M	326.1M	286M
Current Ratio	3.62x	1.96x	1.49x	1.83x	1.37x	1.99x	1.41x	1.88x	1.61x	1.91x
Quick Ratio	2.22x	1.14x	0.81x	0.90x	0.68x	1.03x	0.79x	0.97x	0.78x	0.99x
Cash Conversion Cycle	487.22	322.29	371.97	362.97	383.86	510.84	410.2	396.74	417.07	410.31
Total Non-Current Liabilities+	15.65B	14.63B	11.21B	10.43B	8.8B	9.66B	7.32B	6.68B	6.15B	6.44B
Long-Term Debt	11.5B	10.67B	8.92B	8.41B	6.72B	7.63B	5.46B	5.15B	4.87B	5.34B
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	3.15B	3.03B	1.1B	999.5M	840.1M	790.4M	558.5M	474.8M	357.6M	352.5M
Other Non-Current Liabilities	1.01B	936.3M	1.19B	1.02B	1.24B	1.24B	1.3B	1.05B	925.9M	744.1M
Total Liabilities	17.27B	17.01B	14.28B	12.85B	12.25B	12.22B	10.79B	9.04B	9.01B	8.89B
Total Debt+	11.5B	11.24B	10.14B	8.94B	8.22B	8.13B	7.07B	5.7B	5.77B	6.2B
Net Debt	10.04B	10.61B	9.62B	8.4B	7.6B	7.32B	6.69B	5.32B	5.35B	5.68B
Debt / Equity	1.16x	1.16x	0.86x	0.79x	0.66x	0.67x	0.56x	0.47x	0.46x	0.50x
Debt / EBITDA	9.75x	6.04x	5.45x	8.32x	3.84x	8.28x	3.93x	3.51x	2.59x	2.72x
Net Debt / EBITDA	8.51x	5.70x	5.17x	7.82x	3.55x	7.46x	3.72x	3.28x	2.40x	2.49x
Interest Coverage	1.63x	2.31x	2.46x	0.12x	5.01x	0.39x	4.13x	4.23x	6.35x	5.90x
Total Equity+	9.89B	9.67B	11.74B	11.28B	12.39B	12.2B	12.67B	12.03B	12.48B	12.48B
Equity Growth %	0.51%	-0.02%	0.21%	-0.04%	0.1%	-0.02%	0.04%	-0.05%	0.04%	-0%
Book Value per Share	52.10	47.78	57.61	55.41	59.96	58.93	60.20	57.19	59.52	61.19
Total Shareholders' Equity	9.89B	9.67B	11.74B	11.27B	12.39B	12.19B	12.66B	12.02B	12.48B	12.47B
Common Stock	3M	3.1M	3.1M	3.1M	3.1M	3.1M	3.1M	3.1M	3.2M	3.2M
Retained Earnings	8.35B	8.47B	10.02B	9.49B	10.43B	10.09B	10.29B	9.56B	10.38B	11.1B
Treasury Stock	-6.33B	-6.74B	-6.72B	-6.72B	-6.72B	-6.72B	-6.72B	-6.87B	-7.56B	-8.41B
Accumulated OCI	-329M	-434M	-83.2M	-187.4M	-241.9M	-297.8M	-231.6M	-179.3M	-191M	-262.8M
Minority Interest	1.5M	1M	-300K	4.8M	4.7M	5.2M	5.7M	6.7M	7.7M	8.1M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	849.8M	1.63B	1.58B	1.75B	1.59B	1.2B	1.5B	1.28B	1.58B	1.5B
Operating CF Margin %	0.14%	0.21%	0.2%	0.22%	0.2%	0.2%	0.22%	0.19%	0.21%	0.2%
Operating CF Growth %	-0.2%	0.92%	-0.03%	0.1%	-0.09%	-0.24%	0.24%	-0.14%	0.23%	-0.05%
Net Income	146.2M	304.6M	1.81B	-379.3M	1.13B	-9.2M	445.5M	291.2M	1.03B	905.2M
Depreciation & Amortization	712.4M	1.04B	1.06B	1.04B	1.01B	898.4M	937.7M	926.4M	951.7M	996.3M
Stock-Based Compensation	46.4M	57.3M	53.7M	65.5M	84.3M	73.8M	76M	105M	99.8M	101M
Deferred Taxes	-164M	-153.2M	-1.78B	13.4M	-538.7M	39.4M	-102.1M	-64.4M	-96.3M	-47.7M
Other Non-Cash Items	399.4M	407.7M	364.3M	979.7M	70.1M	631.9M	276.3M	337.9M	-2.5M	0
Working Capital Changes	-290.6M	-23.5M	64.2M	27.6M	-167.5M	-429.8M	-134.2M	-311.4M	-396.2M	-455.4M
Change in Receivables	-56.1M	-141.6M	161.7M	213.6M	-93.8M	-66.2M	-40.8M	-184.7M	-51.9M	-89.7M
Change in Inventory	-205.4M	77.9M	-120.1M	-199.5M	-125.2M	-34.5M	-8.4M	-75.6M	-240.4M	49.9M
Change in Payables	-252M	32.6M	-133.3M	155.9M	-42M	-95.1M	0	0	0	0
Cash from Investing+	-7.56B	-1.69B	-510.8M	-416.6M	-729.3M	-613.8M	-503.6M	-529.2M	-778.9M	-888.1M
Capital Expenditures	-167.7M	-184.7M	-156M	-162.7M	-207.1M	-111.9M	-143.6M	-187.9M	-291.1M	-203.8M
CapEx % of Revenue	0.03%	0.02%	0.02%	0.02%	0.03%	0.02%	0.02%	0.03%	0.04%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	48.2M	-3M	-13.8M	-31.5M	-217.3M	-69.3M	-88.3M	-72.6M	-74.6M	-189.8M
Cash from Financing+	7.14B	-743.2M	-1.21B	-1.3B	-779.9M	-421.8M	-1.31B	-843.8M	-763.5M	-484.5M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-157.1M	-188.4M	-193.6M	-195.2M	-196.7M	-198.5M	-200.1M	-201.2M	-200.9M	-196M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	47.5M	120.3M	231.3M	47.4M	132.9M	29.6M	-50.9M	544.5M	75M	43.2M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	682.1M	1.45B	1.43B	1.58B	1.18B	1.09B	1.35B	1.07B	1.19B	1.14B
FCF Margin %	0.11%	0.19%	0.18%	0.2%	0.15%	0.18%	0.2%	0.15%	0.16%	0.15%
FCF Growth %	-0.26%	1.12%	-0.01%	0.11%	-0.25%	-0.07%	0.23%	-0.21%	0.11%	-0.04%
FCF per Share	3.59	7.15	7.00	7.79	5.71	5.28	6.40	5.07	5.66	5.60
FCF Conversion (FCF/Net Income)	5.78x	5.34x	0.87x	-4.61x	1.40x	-8.67x	3.73x	5.55x	1.54x	1.66x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	1.79%	3.13%	16.95%	-3.3%	9.56%	-1.13%	3.23%	1.87%	8.36%	7.24%
Return on Invested Capital (ROIC)	2.61%	3.06%	2.88%	0.12%	4.3%	0.32%	3.32%	2.85%	5.45%	5.36%
Gross Margin	69.98%	68.94%	72.67%	71.36%	71.78%	70.23%	71.29%	70.9%	71.82%	71.46%
Net Margin	2.45%	3.99%	23.24%	-4.78%	14.18%	-2.27%	5.88%	3.33%	13.85%	11.77%
Debt / Equity	1.16x	1.16x	0.86x	0.79x	0.66x	0.67x	0.56x	0.47x	0.46x	0.50x
Interest Coverage	1.63x	2.31x	2.46x	0.12x	5.01x	0.39x	4.13x	4.23x	6.35x	5.90x
FCF Conversion	5.78x	5.34x	0.87x	-4.61x	1.40x	-8.67x	3.73x	5.55x	1.54x	1.66x
Revenue Growth	28.34%	27.85%	1.76%	1.66%	0.62%	-23.24%	11.42%	1.65%	6.55%	3.85%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Knees	2.28B	2.75B	2.74B	2.77B	2.81B	2.39B	2.65B	2.78B	3.04B	3.17B
Knees Growth	-	20.87%	-0.54%	1.34%	1.31%	-14.96%	10.80%	4.92%	9.36%	4.45%
Hips	1.54B	1.87B	1.88B	1.92B	1.94B	1.75B	1.86B	1.89B	1.97B	2B
Hips Growth	-	21.51%	0.60%	2.25%	0.71%	-9.54%	6.03%	2.09%	3.82%	1.62%
S E T	1.21B	1.65B	1.71B	1.75B	1.8B	1.32B	1.73B	1.7B	1.75B	1.87B
S E T Growth	-	35.44%	3.87%	2.50%	2.51%	-26.38%	30.70%	-1.80%	3.29%	6.45%
Other Product Category	228.8M	328.8M	320.7M	310.9M	280M	518.5M	595.6M	570M	636M	640.3M
Other Product Category Growth	-	43.71%	-2.46%	-3.06%	-9.94%	85.18%	14.87%	-4.30%	11.58%	0.68%

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Americas	3.11B	3.95B	3.95B	4.84B	4.88B	4.34B	4.8B	4.3B	4.62B	4.79B
Americas Growth	-	26.96%	0.09%	22.43%	0.80%	-11.08%	10.72%	-10.51%	7.65%	3.69%
E M E A	1.3B	1.57B	1.52B	1.8B	1.75B	1.39B	1.67B	1.46B	1.59B	1.69B
E M E A Growth	-	20.20%	-2.81%	18.38%	-3.05%	-20.36%	20.11%	-12.84%	9.32%	6.20%
Asia Pacific	881.6M	1.09B	1.16B	1.29B	1.36B	1.3B	1.36B	1.19B	1.18B	1.19B
Asia Pacific Growth	-	23.89%	6.05%	11.70%	5.08%	-4.54%	5.17%	-12.98%	-0.85%	1.28%

Frequently Asked Questions

Valuation & Price

Zimmer Biomet Holdings, Inc. (ZBH) has a price-to-earnings (P/E) ratio of 19.9x. This is roughly in line with market averages.

Growth & Financials

Zimmer Biomet Holdings, Inc. (ZBH) reported $8.01B in revenue for fiscal year 2024. This represents a 80% increase from $4.45B in 2011.

Zimmer Biomet Holdings, Inc. (ZBH) grew revenue by 3.8% over the past year. Growth has been modest.

Yes, Zimmer Biomet Holdings, Inc. (ZBH) is profitable, generating $805.2M in net income for fiscal year 2024 (11.8% net margin).

Dividend & Returns

Yes, Zimmer Biomet Holdings, Inc. (ZBH) pays a dividend with a yield of 1.09%. This makes it attractive for income-focused investors.

Zimmer Biomet Holdings, Inc. (ZBH) has a return on equity (ROE) of 7.2%. This is below average, suggesting room for improvement.

Zimmer Biomet Holdings, Inc. (ZBH) generated $1.60B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...